98%
921
2 minutes
20
We analyzed recent changes in the incidence of glaucoma and associated visual impairment (VI) in Korea over a 16-year period. We utilized nationwide, longitudinal cohort data from the Korea National Health Insurance System (KNHIS) National Health Screening Cohort from 2004 to 2019 to evaluate the age-standardized incidence rate (SIR) of glaucoma and glaucoma-related VI. VI was determined based on KNHIS health examinations and the National Registry for Visual Disability. The incidence rates were estimated per 100,000 person-years. Joinpoint regression analysis was applied to assess significant changes in incidence trends, and subgroup analyses were conducted by age and sex. The age-SIR of glaucoma increased from 864.1 per 100,000 in 2004 to a peak of 1101.1 in 2016, followed by a decline to 978.9 in 2019. Joinpoint regression identified a significant rise from 2007 to 2015 (annual percent change [APC]: +3.92%), with a subsequent decline (APC: -3.30%). The incidence of glaucoma-related severe VI decreased from 26.23 per 100,000 in 2004 to 8.76 in 2012, remaining stable thereafter at 12.49 in 2019. The VI-to-incidence ratio also declined from 0.030 in 2004 to 0.009 in 2012, which remained stable thereafter at 0.013 in 2019. Females consistently exhibited higher glaucoma incidence but lower VI rates than males. These recent trends highlight the evolving landscape of glaucoma epidemiology in Korea and underscore the need for sustained early detection efforts and optimized patient management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12386786 | PMC |
http://dx.doi.org/10.3390/jcm14165691 | DOI Listing |
Zhonghua Yan Ke Za Zhi
September 2025
Aier Glaucoma Institute, Hunan Engineering Research Center for Glaucoma with Artificial Intelligence in Diagnosis and Application of New Materials, Changsha Aier Eye Hospital, Changsha 410015, China.
As the world's leading irreversible blinding eye disease, glaucoma is predominantly managed with pharmaceutical interventions in clinical practice. However, long-term use of traditional eye drops containing preservatives (e.g.
View Article and Find Full Text PDFMicrobiol Spectr
September 2025
Department of Ophthalmology, Mason Eye Institute, University of Missouri School of Medicine, Columbia, Missouri, USA.
Unlabelled: Zika virus (ZIKV) is the lone member of Flavivirus family known to cause congenital glaucoma following exposure. The molecular mechanisms of ZIKV-induced glaucoma remain elusive, with no known therapeutic modalities. Autophagy plays a dual role in viral infections and glaucoma pathogenesis.
View Article and Find Full Text PDFTransl Vis Sci Technol
September 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, People's Republic of China.
Purpose: The purpose of this study was to estimate the correlations between macular optical coherence tomography (OCT)-derived metrics and incident glaucoma risk in myopic eyes.
Methods: This longitudinal observational study included 24,181 individuals with myopia (spherical equivalence [SE] ≤ -0.5 diopters [D]) from the UK Biobank study.
Ophthalmol Glaucoma
September 2025
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, England; Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South Wales, Australia.
Purpose: To compare the long-term safety of MicroShunt implantation with trabeculectomy in eyes with primary open-angle glaucoma (POAG).
Methods: This was a 3-year observational extension of a 2-year prospective randomized trial comparing clinical outcomes of MicroShunt implantation with trabeculectomy, both augmented with mitomycin C. Adverse events (AEs), intraocular pressure (IOP), and IOP-lowering medication use were recorded 36, 48, and 60 months after initial randomization.
Int Ophthalmol
September 2025
Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, 200 Hawkins Dr, 11290A PFP, Iowa City, IA, 52242, USA.
Purpose: To study clinical characteristics and outcomes of penetrating keratoplasty (PK) and deep anterior lamellar keratoplasty (DALK) wound dehiscence.
Methods: This retrospective case series assessed PK and DALK recipients with wound dehiscence at a single institution. We evaluated relationships between dehiscence etiologies, transplant indications, ocular/systemic comorbidities, keratoplasty type, and adverse post-dehiscence outcomes, especially graft failure and visual loss.